Oral medication for early mesothelioma in BAP1 gene carriers
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests an oral medication called decitabine/cedazuridine (INQOVI) that may help delay or prevent progression in people with early-stage mesothelioma who carry a BAP1 mutation. The treatment is given as a pill and aims to reactivate genes that may help control cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must carry a BAP1 gene mutation.
- You must have a very early-stage mesothelioma (or another early-stage BAP1-related cancer) found before symptoms, not yet needing standard treatment.
- You must be 18 years or older.
- You must be willing to have two minimally invasive procedures (thoracoscopy or laparoscopy) to assess the disease before and after treatment.
- You must have adequate organ function (heart, lungs, kidneys, liver) and be otherwise in reasonably good health.
- You must be willing to use effective contraception during and shortly after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well advanced scans, liquid biopsy tests, and small follow-up procedures can find early mesothelioma in people with a high-risk BAP1 gene condition. It may help catch cancer earlier when treatment could work better.
This study follows people with a harmful (deleterious) BAP1 gene change to learn how it affects health over time. It may help researchers better understand mesothelioma risk and the long-term outcomes for families with this genetic mutation.
This trial tests a new drug called BMS-986504 in people whose mesothelioma has come back after treatment and whose tumors lack a protein called MTAP. The drug may help by blocking a specific pathway that these cancer cells need to grow.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy and a targeted therapy for people with advanced mesothelioma who have not had treatment before. The goal is to see if this combination can shrink tumors and help people live longer.
This trial tests whether olaparib (a cancer medicine) can help control malignant mesothelioma that has specific DNA changes. You must have already had platinum chemotherapy and your cancer must be “platinum-sensitive,” plus your tumor (or family/genetic cells) must show certain gene problems.
This early-stage trial tests VT3989 in people with specific advanced (metastatic or unresectable) cancers. It may help shrink tumors or slow cancer growth in patients who fit the genetic or diagnosis-specific requirements.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.